Midday Movers: Pump Up the Volume
Several small-cap stocks were moving on above-average volume during Monday's session.
01:36PM 10/19/09
Odds, Analaysts Against Human Genome's Lupus Drug
Human Genome's drug Benlysta provokes nearly universal negativity among analysts.
10:37AM 07/15/09
Genentech Lupus Data Fall Short
Genentech and Biogen Idec report that a phase III study Rituxan failed to meet the primary endpoint as a treatment for patients with a form of lupus.
05:34PM 03/11/09
Human Genome's Plan B: Lupus Drug
Human Genome Science's next shot at a turnaround lies with a risky phase III study of a lupus drug.
11:30AM 03/11/09
BioTalk: Something Old, Something New
By Adam Feuerstein | By Elizabeth Trotta
Adam Feuerstein, manager of the Biotech Select Portfolio, discusses La Jolla's trial blowup and the latest act in the Genentech-Roche saga.
11:59AM 02/15/09
BioMarin Buys Rights to Long-Delayed La Jolla Drug
The company has licensed worldwide commercial rights to Riquent, an experimental lupus drug from La Jolla Pharmaceuticals.
05:08PM 01/06/09
This Week's 'Barron's' Roundup
Hedge fund manager Sy Jacobs discusses financial stocks, Barron's goes bullish on Mohawk, plus much more.
09:59AM 05/25/08
Feuerstein's Biotech-Stock Mailbag
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
11:10AM 05/03/08
Positive Drug Data Lift La Jolla Pharma
Its lupus treatment is well tolerated in three reports.
12:09AM 08/07/07
Prior leaders in energy, utilities and mining lead a retreat. Bob Faulkner breaks down the tech tumble. Plus, a bonus 'Should I Buy It?' segment.
12:09AM 08/07/07
Friday's Small-Cap Winners & Losers
Image Entertainment climbs on news it will be acquired.
01:26AM 06/20/07
Worrying about Amgen, Geron's pipeline and the year in biotech calendar.
01:24AM 06/20/07



Connect with TheStreet